The FDA clearances are a positive product milestone for RadNet's AI subsidiary, but the lack of revenue guidance or adoption metrics limits near-term stock impact. Monitor future earnings calls for updates on commercial deployment and any contribution to RadNet's Digital Health segment. Historical poor performance on RDNT calls (avg T+20 -11.7%) suggests caution despite the bullish event.
Price Chart
Executive Summary
DeepHealth, a wholly owned subsidiary of RadNet (RDNT), received FDA 510(k) clearances for two new breast imaging AI functionalities: BAC Assessment (identifies breast arterial calcifications as a cardiovascular risk indicator) and Mammo Dx (prior exam integration for improved cancer detection). The clearances expand the Breast Suite but no financial terms or revenue impact were disclosed.
Key Facts
- FDA 510(k) clearance for BAC Assessment, which automatically identifies breast arterial calcifications on standard mammograms with >90% sensitivity and >88% specificity.
- FDA 510(k) clearance for Mammo Dx (formerly ProFound Pro), which integrates prior exams to track lesions and improve cancer detection rates.
- Both functionalities are now commercially available in the U.S. and will be deployed across RadNet imaging centers.
- The clearances add to DeepHealth's Breast Suite, which already includes breast density assessment, risk assessment, and workflow tools.
Financial Impact
No direct financial impact stated; potential for incremental AI licensing revenue or increased imaging volume at RadNet centers, but unquantified.
Risk Factors
- Adoption uncertainty: no disclosed contracts or revenue projections for the new AI tools.
- Competitive landscape: other AI breast imaging solutions exist (e.g., Hologic, iCAD).
- Historical stock underperformance: past bullish calls on RDNT have resulted in negative T+20 returns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3317350 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $77.28 $71.97 | ▼ −6.87% | ▼ −5.96% | $69.93 (−9.51%) |
Aug 9, 2026 7w ago | Press Release | $77.28 $71.97 | ▼ −6.87% | ▼ −5.96% | $69.93 (−9.51%) |
Jun 25, 2026 14w ago | Press Release | $60.01 $60.98 | ▲ +1.62% | ▲ +1.09% | $69.93 (+16.53%) |
Jun 10, 2026 16w ago | 8-K | $58.20 $65.94 | ▲ +13.30% | ▲ +11.41% | $69.93 (+20.15%) |
Jun 3, 2026 17w ago | 8-K | $51.87 $68.75 | ▲ +32.54% | ▲ +33.54% | $69.93 (+34.82%) |
May 11, 2026 20w ago | 8-K | $55.90 $56.18 | ▲ +0.50% | ▲ +0.81% | $69.93 (+25.10%) |
May 10, 2026 20w ago | Press Release | $55.90 $56.18 | ▲ +0.50% | ▲ +0.81% | $69.93 (+25.10%) |
Apr 28, 2026 22w ago | Press Release | $57.89 $53.84 | ▼ −7.00% | ▼ −12.45% | $69.93 (+20.80%) |
Apr 20, 2026 23w ago | DEFA14A | $57.51 $54.17 | ▼ −5.81% | ▼ −10.72% | $69.93 (+21.60%) |
Mar 11, 2026 29w ago | Press Release | $59.78 $55.43 | ▼ −7.28% | ▼ −9.25% | $69.93 (+16.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access